Application of oxymatrine in medicines for treating neonatal hypoxic ischemic brain damages

A technology of oxymatrine and hypoxia-ischemia, applied in drug combinations, medical preparations containing active ingredients, pharmaceutical formulas, etc., to achieve the effect of reducing the volume of cerebral infarction and the rate of apoptosis

Inactive Publication Date: 2015-07-01
NINGXIA MEDICAL UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, studies at home and abroad have found that oxymatrine also has antiarrhythmic, positive inotropic properties, improves hemodynamics, inhibits lipid peroxidation, lowers blood pressure, lowers heart rate, inhibits myocardial cell apoptosis, and protects myocardial ischemia. There are many pharmacological activities and clinical functions such as infarction and infarction, but there is no literature report about its protective effect on neonatal ischemic-hypoxic brain injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of oxymatrine in medicines for treating neonatal hypoxic ischemic brain damages
  • Application of oxymatrine in medicines for treating neonatal hypoxic ischemic brain damages
  • Application of oxymatrine in medicines for treating neonatal hypoxic ischemic brain damages

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Oxymatrine is used as a medicine for treating neonatal hypoxic-ischemic brain injury. The structural formula of oxymatrine is shown in formula (1):

[0038]

[0039] Among them, neonatal hypoxic-ischemia refers to acute hypoxic-ischemic brain injury, and the single application dose of oxymatrine is limited to the dose that does not cause blood sugar drop, and the single application dose of oxymatrine is 30mg / kg body weight, the dosage form of the drug is an injection.

Embodiment 2

[0041] Oxymatrine is used as a medicine for treating neonatal hypoxic-ischemic brain injury. The structural formula of oxymatrine is shown in formula (1):

[0042]

[0043] Among them, neonatal hypoxic-ischemia refers to hypoxic-ischemic brain injury in the repair period, and the single application dose of oxymatrine is limited to the dose that does not cause blood sugar drop, and the single application dose of oxymatrine is 60 mg / day for newborn rats. kg body weight, the dosage form of the drug is injection powder dosage form.

Embodiment 3

[0045] Oxymatrine is used as a medicine for treating neonatal hypoxic-ischemic brain injury. The structural formula of oxymatrine is shown in formula (1):

[0046]

[0047] Among them, neonatal hypoxic-ischemic brain injury refers to neonatal hypoxic-ischemic brain injury in the repair period, and the single application dose of oxymatrine is limited to the dose that does not cause blood sugar drop, and the single application dose of oxymatrine is limited to the newborn infant. Rat 120mg / kg body weight, the dosage form of the drug is injection powder dosage form.

[0048] The following animal experiment has further illustrated the effect of above-mentioned embodiment 1-3:

[0049] 1. Experimental materials

[0050] 1.1 Animal handling

[0051] 7-day-old neonatal SD rats, weighing 12-18 g, were purchased from the Experimental Animal Center of Ningxia Medical University, animal production license number: NCXK (Ning) 2013-0005. Feeding conditions include standard feed, tap w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of oxymatrine in medicines for treating neonatal hypoxic ischemic brain damages. An experiment result shows that oxymatrine has a certain dose-effect correlation when used in a safe dose range; when the dose is 120mg / kg of body weight, the volume of ischemia area cerebral infarction and neuron apoptosis rate can be reduced; pathological damages to brain tissues can be relieved; the activity of antioxidase in the brain tissues can be improved; and the content of malondialdehyde is lowered. The oxymatrine has the effects of preventing injuries and deaths caused by neonatal hypoxic ischemic brain damages and promoting neural functional recovery.

Description

technical field [0001] The invention relates to the application of oxymatrine, in particular to the application of oxymatrine as a drug for treating neonatal hypoxic-ischemic brain injury. Background technique [0002] Neonatal hypoxic-ischemic brain damage (Hypoxic-ischemic Brain Damage, HIBD) refers to a neonatal brain hypoxic-ischemic damage caused by perinatal asphyxia, a disease with abnormal central nervous system, and its pathogenesis is complex , high mortality, seriously affecting the quality of life of newborns. Statistics show that the incidence of asphyxia in live births is about 1-3‰, about 15-25% of asphyxiated newborns die due to HIBD, and the proportion of survivors with permanent neuropsychological disorders due to mental retardation, cerebral palsy or epilepsy up to 25%. Since the pathogenesis of neonatal HIBD is still unclear, there are no fundamental and effective measures for its post-injury treatment so far. At present, comprehensive treatment is mai...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61P9/10A61P25/00
Inventor 余建强赵鹏周茹郑婕李玉香吴璟乔海琦刘河涛
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap